| Date |
Subject |
Media |
| 2025-09-10 |
Inventec Appliances Deploys Thousands of Infusion Pumps at Chi-Mei Hospital to Enhance Care Efficiency
|
Inventec Appliances, a subsidiary of the Inventec Group, announced that its SmartMed Infusion System has been officially deployed at Chi-Mei Hospital, making it the first hospital in southern Taiwan to adopt this smart infusion solution. This initiative reflects Chi-Mei Hospital’s proactive approach to smart healthcare development and underscores its strong commitment to clinical medication safety and patient care quality. |
| 2025-09-10 |
Climate Crisis Is a Health Crisis! Chih-Hung Chen: Medical Resilience Cannot Wait
|
The impact of climate disasters on Taiwan is intensifying. Since July, the island has been battered by three consecutive typhoons—Danas, Vipa, and Yangliu—with the coastal regions of Chiayi and Tainan suffering severe agricultural losses and infrastructure damage due to heavy rainfall. Experts warn that this is not only an environmental challenge but also a serious public health crisis. |
| 2025-09-08 |
Polaris Group-KY’s New Drug for Malignant Pleural Mesothelioma Enters FDA Substantive Review; U.S. Distribution Licensing to Accelerate
|
Polaris Group-KY announced that its new drug Pegargiminase (ADI-PEG 20), developed for the treatment of malignant pleural mesothelioma, has officially entered the substantive review stage with the U.S. FDA. This news drove the company’s stock to surge to its daily limit immediately after opening. If the FDA review and the planned U.S. inspection next February proceed smoothly, the drug could receive approval as early as the first half of next year, while discussions on U.S. market distribution licensing are expected to accelerate, potentially being finalized in Q1 2026. |
| 2025-09-08 |
Taipei Veterans General Hospital Breaks Ground on Boron Neutron Capture Cancer Therapy Center; NT$1.2 Billion Investment to Complete in Two Years, Achieving Comprehensive Cancer Treatment
|
Taipei Veterans General Hospital (TVGH) has officially commenced construction of its Boron Neutron Capture Therapy (BNCT) Center, scheduled for completion and operation in 2027 (Year 116 of the Republic of China calendar). Once completed, TVGH will become one of the very few medical institutions worldwide equipped with both heavy-ion therapy and BNCT, offering comprehensive, state-of-the-art radiation oncology capabilities and elevating Taiwan to the forefront of global cancer radiation treatment, education, and research. |
| 2025-09-08 |
Foxconn Technology Group Brings Smart Medical Devices to Market, Partners with NOBEL to Launch CoDoctor Eye
|
Foxconn Technology Group is taking its next step in smart healthcare. Barry Chlang, General Manager of the B Business Group, announced yesterday that the company has partnered with NOBEL Eyewear to launch the CoDoctor Eye fundus photography device. This device reduces the size of traditional 40-kg equipment to just 700 grams, successfully transforming a hospital-bound diagnostic tool into a portable digital health solution, marking a milestone for Foxconn’s smart healthcare products moving from R&D to practical application. |
| 2025-09-08 |
Bora Pharmaceuticals’ SunWay Biotech Invests NT$650 Million in Wonders Company Ltd., Acquires 30% Stake and Board Seat
|
SunWay Biotech, a subsidiary of Bora Pharmaceuticals Group, announced on the 19th that its board of directors has approved a strategic investment in Wonders Company Ltd. With a cash injection of NT$650 million, SunWay will acquire a 30% stake in the company, along with one board seat. The transaction is expected to close in September. |
| 2025-09-08 |
Syncell Partners with Thermo Fisher to Pioneer Breakthrough in Subcellular High-Resolution Spatial Proteomics
|
Biotech startup Syncell announced on the 18th that it has signed a strategic co-marketing partnership with Thermo Fisher Scientific, a global leader in scientific services, to integrate its Microscoop spatial protein purification technology with Thermo Fisher’s Orbitrap Astral mass spectrometry series. The collaboration will deliver a next-generation subcellular high-resolution spatial proteomics solution. |
| 2025-09-08 |
BioGend’s Revocart Wins Hong Kong Medical Device License
|
BioGend Therapeutics announced yesterday (18th) that its cartilage regeneration product Revocart has successfully obtained a medical device license in Hong Kong. The company will now accelerate promotion and sales in Hong Kong, Macau, and China’s Greater Bay Area (GBA). |
| 2025-09-08 |
Lotus Pharmaceutical’s Multiple Growth Engines in Asia and Export Markets Drive Second-Half Momentum; Exchange Rates Pressure Revenue but Margins Remain Intact
|
Specialty generic drugmaker Lotus Pharmaceutical spokesperson Bjartur Shen said at the company’s earnings call on the 15th that exchange rate fluctuations will trim this year’s revenue growth target by about 2–3 percentage points, but margins will remain unaffected. The second-quarter gross margin decline reflected the timing of revenue recognition for the blood cancer drug Lenalidomide, while this year’s peak sales are expected in the fourth quarter. Exports of addiction treatment drugs are likely to rise in the second half due to supply disruptions among competitors. New products such as Nintedanib will begin contributing this year, with larger volumes expected next year. Coupled with successful business integration and M&A progress in Asian markets, the company remains optimistic for the second half. |
| 2025-09-08 |
Injectables/CDMO Becoming Growth Driver, Formosa Laboratories Poised for New Revenue Momentum
|
Formosa Laboratories, a pharmaceutical company that has expanded from active pharmaceutical ingredients (APIs) into injectables, saw its net income after tax turn negative in the first half of the year due to financial asset losses and foreign exchange impacts. However, institutional investors remain optimistic about the company’s tangible benefits from CDMO business expansion and recent certification of its injectable plant. Revenue in New Taiwan dollars is still expected to remain stable year-on-year in 2024, with hopes that, in the medium term, income from CDMO services and injectables will replace APIs as the main growth engine. |
